Based on the information from DrugPatentWatch.com, Dupixent (dupilumab) is a medication used to treat several medical conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps [1]. The drug is jointly developed by Sanofi and Regeneron Pharmaceuticals [1].
According to the financial reports of Sanofi, Dupixent sales have shown a steady increase throughout 2020. The net sales for Dupixent in Q1 2020 were €619 million (approximately $713 million), representing a 92.5% year-over-year increase [2]. In Q2 2020, Dupixent sales amounted to €952 million (approximately $1,095 million), marking a 122.5% year-over-year growth [3]. In Q3 2020, Dupixent sales continued to rise, reaching €1,283 million (approximately $1,471 million), indicating a 133.4% year-over-year increase [4]. Although Sanofi has not yet released the official Q4 2020 financial report, the company's press release in January 2021 announced that Dupixent generated sales of €1,533 million (approximately $1,815 million) in Q4 2020, reflecting a 19% year-over-year growth [5].
In summary, Dupixent sales increased in all four quarters of 2020, with the following sales figures:
- Q1 2020: €619 million ($713 million)
- Q2 2020: €952 million ($1,095 million)
- Q3 2020: €1,283 million ($1,471 million)
- Q4 2020: €1,533 million ($1,815 million)
Sources:
1. "[Dupixent (dupilumab).](https://www.drugpatentwatch.com/drugs/dupixent)" DrugPatentWatch.com.
2. "[Sanofi reports sales of €8,188 million for the first quarter of 2020.](https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-29-21-00-00--sanofi-reports-sales-of-euro-8-188-million-for-the-first-quarter-of-2020)" Sanofi. April 29, 2020.
3. "[Sanofi reports sales of €8,485 million for the second quarter of 2020.](https://www.sanofi.com/en/media-room/press-releases/2020/2020-07-30-21-00-00--sanofi-reports-sales-of-euro-8-485-million-for-the-second-quarter-of-2020)" Sanofi. July 30, 2020.
4. "[Sanofi reports sales of €8,833 million for the third quarter of 2020.](https://www.sanofi.com/en/media-room/press-releases/2020/2020-10-29-21-00-00--sanofi-reports-sales-of-euro-8-833-million-for-the-third-quarter-of-2020)" Sanofi. October 29, 2020.
5. "[Sanofi reports sales of €10,045 million for the fourth quarter of 2020.](https://www.sanofi.com/en/media-room/press-releases/2021/2021-01-28-21-00-00--sanofi-reports-sales-of-euro-10-045-million-for-the-fourth-quarter-of-2020)" Sanofi. January 28, 2021.